health | mecfa 3/4

MECFA Blog

Phase 3 Trial of RDEB Therapy EB-101 to Start in 2019, Abeona Therapeutics Says

Abeona Therapeutics plans to start a Phase 3 trial in 2019 testing the cell therapy candidate EB-101 as a treatment for recessive...

Triple Combo Treatment Improves Lung Function in Patients with Cystic Fibrosis

An investigational triple combination treatment regimen for cystic fibrosis (CF) improved patients’ lung function in 2 phase 3 studies,...

NuvoAir Redefines Home Monitoring for Cystic Fibrosis Patients

STOCKHOLM--(BUSINESS WIRE)--Dec 4, 2018--THE FINDINGS from a pilot study into a new way of caring for those with cystic fibrosis (CF)...

Study Reveals How Cystic Fibrosis Affects Young Women’s Sexual Health

Girls with cystic fibrosis (CF) reach puberty six to eight months later than healthy girls, about 16 percent of young females with CF...

Cystic Fibrosis Patients Exposed to Higher Risks of Liver Cancer

Researchers from Colorado, in the United States, shared the results of a study that showed that patients with cystic fibrosis would be at...

New Mucus Study Could Hold the Key to Clearing Your Phlegm

Mucus, you fickle fiend—usually, you’re there keeping us safe from whatever nasties sneak inside of us. But then you turn, becoming a...

Avycaz May Be Effective for Multidrug-resistant P. aeruginosa Infections in CF Patients, Study Sugge

Antibacterial Avycaz (ceftazidime-avibactam) showed significant in vitroefficacy against multidrug-resistant Pseudomonas aeruginosa...

Decibel Obtains Exclusive License for ORC-13661 for Prevention of Antibiotic-related Ototoxicity

Decibel Therapeutics received worldwide, exclusive rights to develop and commercialize ORC-13661, Oricula Therapeutics’ investigational...

Committee approves 8 additional conditions for treatment with medical marijuana

A legislative committee approved eight additional conditions — six just for adults and two for adults and children — that will soon be...

MRSA Difficult to Eradicate, Even With Multimodal Antibiotics, CF Study Finds

Up to one month of treatment with inhaled vancomycin, the antibiotic of choice for treating most methicillin-resistant Staphylococcus...

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p